Department of Pathology, New York University School of Medicine, New York, United States
Simranjit X Singh
Department of Pathology, New York University School of Medicine, New York, United States
Shawn M Davidson
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, United States; Department of Biology, Massachusetts Institute of Technology, Cambridge, United States
Douglas Biancur
Department of Pathology, New York University School of Medicine, New York, United States
Betul S Guzelhan
Department of Pathology, New York University School of Medicine, New York, United States
Samantha W Alvarez
Department of Pathology, New York University School of Medicine, New York, United States
Warren L Wu
Department of Pathology, New York University School of Medicine, New York, United States
Triantafyllia R Karakousi
Department of Pathology, New York University School of Medicine, New York, United States
Anastasia Maria Zavitsanou
Department of Pathology, New York University School of Medicine, New York, United States
Julian Ubriaco
Department of Pathology, New York University School of Medicine, New York, United States
Alexander Muir
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, United States
Dimitris Karagiannis
Department of Pathology, New York University School of Medicine, New York, United States
Patrick J Morris
NIH Chemical Genomics Center, National Center for Advancing Translational Sciences, Bethesda, United States; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, United States
Craig J Thomas
NIH Chemical Genomics Center, National Center for Advancing Translational Sciences, Bethesda, United States; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, United States
Richard Possemato
Department of Pathology, New York University School of Medicine, New York, United States
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, United States; Department of Biology, Massachusetts Institute of Technology, Cambridge, United States
During tumorigenesis, the high metabolic demand of cancer cells results in increased production of reactive oxygen species. To maintain oxidative homeostasis, tumor cells increase their antioxidant production through hyperactivation of the NRF2 pathway, which promotes tumor cell growth. Despite the extensive characterization of NRF2-driven metabolic rewiring, little is known about the metabolic liabilities generated by this reprogramming. Here, we show that activation of NRF2, in either mouse or human cancer cells, leads to increased dependency on exogenous glutamine through increased consumption of glutamate for glutathione synthesis and glutamate secretion by xc- antiporter system. Together, this limits glutamate availability for the tricarboxylic acid cycle and other biosynthetic reactions creating a metabolic bottleneck. Cancers with genetic or pharmacological activation of the NRF2 antioxidant pathway have a metabolic imbalance between supporting increased antioxidant capacity over central carbon metabolism, which can be therapeutically exploited.